All In Biotech

Investigational drug · Phase 2

Neflamapimod

Also called: VX-745

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

4

1 still active

All registered trials

8

Any phase or sponsor naming "Neflamapimod"

First trial start

2023

May 1, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Neflamapimod", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
  • Moderate to Severe Acute Ischaemic Stroke
  • Ischaemic Stroke
  • Dementia With Lewy Bodies
  • Dementia With Lewy Bodies (DLB)

Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Neflamapimod" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 59 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.